Veramarx is developing a more sensitive, specific, cost-effective, high throughput diagnostic for the early detection of Lyme disease during the critical 6-8 week window of opportunity for treatment. Our approach is based on cutting-edge technologies and measures both the host’s immediate immune response to the infection and Borrelia burgdorferi-specific proteins. Unlike current tests, we are not betting on single marker picking up all cases of Lyme disease regardless of stage and severity. Instead, we are backing many horses in the race by measuring multiple biomarkers that reflect different aspects of the disease process. We are confident that no single marker can reflect the complexity and diversity of the infection.
Our blood test will target traditional doctor's offices and clinics in addition to Lyme literate doctors and is expected to be sold around the world.